Last reviewed · How we verify

Jevtana — Competitive Intelligence Brief

Jevtana (Jevtana) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

discontinued Tubulin beta Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Jevtana (Jevtana) — Bayer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Jevtana TARGET Jevtana Bayer discontinued Tubulin beta
Adcetris brentuximab-vedotin Pfizer marketed CD30-directed Immunoconjugate [EPC] Tubulin beta 2011-01-01
Jevtana Kit cabazitaxel Accord Hlthcare marketed Microtubule Inhibitor Tubulin beta 2010-01-01
Halaven ERIBULIN Eisai marketed Microtubule Inhibitor Tubulin beta 2010-01-01
Taxol nab-paclitaxel Pfizer marketed Microtubule Inhibitor Tubulin beta-3 chain 1992-01-01
Taxol paclitaxel Pfizer marketed Microtubule Inhibitor [EPC] Tubulin beta-3 chain 1992-01-01
Trastuzuma Trastuzuma Fudan University marketed Receptor tyrosine-protein kinase erbB-2, Tubulin beta

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Jevtana — Competitive Intelligence Brief. https://druglandscape.com/ci/jevtana. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: